ORTX Company Profile and Key Details
Orchard Therapeutics plc
ORTX Stock Price Chart
Stock Price Today
Orchard Therapeutics plc (ORTX) stock surged +0.30%, trading at $16.70 on NASDAQ, up from the previous close of $16.65. The stock opened at $16.65, fluctuating between $16.64 and $16.72 in the recent session.
Stock Snapshot
Stock Price History Chart
Contact Details
About Company
Orchard Therapeutics plc, a biopharmaceutical company, develops gene therapies for serious and life-threatening rare diseases in the United Kingdom, European Union, and the United States. The company's gene therapy approach seeks to transform a patient's hematopoietic stem cells into a gene-modified cellular drug product to treat the patient's disease through a single administration. It provides Strimvelis, a gammaretroviral-based product for the treatment of adenosine deaminase-severe combined immunodeficiency (ADA-SCID). The company's clinical development products comprise OTL-101 for the treatment of ADA-SCID; OTL-200 to treat metachromatic leukodystrophy; OTL-103 for the treatment of Wiskott-Aldrich syndrome; OTL-102 for X-linked chronic granulomatous disease; and OTL-300 for transfusion-dependent beta-thalassemia. Its preclinical programs include OTL-203 for mucopolysaccharidosis type I, OTL-201 for mucopolysaccharidosis type MPS-IIIA, and OTL-202 for mucopolysaccharidosis type IIIB. It has a strategic collaboration agreement with Pharming Group N.V. for research, development, manufacturing, and commercialization of OTL-105, an investigational ex vivo autologous hematopoietic stem cell gene therapy for the treatment of hereditary angioedema. The company was formerly known as Orchard Rx Limited. Orchard Therapeutics plc was founded in 2015 and is headquartered in London, the United Kingdom.
Company Information
| Employees | 166 |
| Beta | 0.55 |
| Sales or Revenue | $6.99M |
| 5Y Sales Change% | 0% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Biotechnology |
Frequently Asked Questions
Orchard Therapeutics plc (NASDAQ: ORTX) stock price is $16.70 in the last trading session. During the trading session, ORTX stock reached the peak price of $16.72 while $16.64 was the lowest point it dropped to. The percentage change in ORTX stock occurred in the recent session was 0.3% while the dollar amount for the price change in ORTX stock was $0.05.
The NASDAQ listed ORTX is part of Biotechnology industry that operates in the broader Healthcare sector. Orchard Therapeutics plc designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Dr. Bobby Gaspar M.D., Ph.D.
Chief Executive Officer, Member of Scientific Advisory Board & Executive Director
Dr. Nicoletta Loggia Ph.D., R.Ph.
Chief Technical Officer
Ms. Renee T. Leck
Director of Investor Relations
Dr. Leslie Meltzer Ph.D.
Chief Medical Officer
Mr. Robin Kenselaar
Senior Vice President & GM of EMEA Commercial Operations
Mr. Frank E. Thomas
Pres & Chief Operating Officer
Mr. Braden Parker
Chief Commercial Officer
Mr. John Cerio
Chief Human Resource Officer
Dr. Nicoletta Loggia Ph.D.
Chief Technical Officer
Benjamin Navon
Director of Corporation Communications
Dr. Fulvio Mavilio Ph.D.
Chief Scientific Officer
ORTX's closing price is 293.87% higher than its 52-week low of $4.24 where as its distance from 52-week high of $16.72 is -0.12%.
Number of ORTX employees currently stands at 166.
Official Website of ORTX is: https://www.orchard-tx.com
ORTX could be contacted at phone 442 038 088286 and can also be accessed through its website. ORTX operates from 108 Cannon Street, London, EC4N 6EU, United Kingdom.
ORTX stock volume for the day was 372.35K shares. The average number of ORTX shares traded daily for last 3 months was 105.22K.
The market value of ORTX currently stands at $380.11M with its latest stock price at $16.70 and 22.76M of its shares outstanding.
Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.
© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com